By: Daniel Trecroci
In August 2005, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved ACTOplus Met for the treatment of type 2 diabetes.
The new medication combines the two popular type 2 drugs Actos (pioglitazone HCl) and metformin HCl, providing convenience to patients.
ACTOplus met will be available in two dosages of pioglitazone with metformin: 15 mg/500 mg and 15 mg/850 mg. The medication is taken once a day or in divided doses.
According to Takeda, a small number of people who have taken metformin, a component of ACTOplus met, have developed a rare but serious condition called lactic acidosis—a buildup of lactic acid in the blood, which can be fatal in about half of cases. ACTOplus met should not be used in people with kidney disease or in people 80 years of age and older who have any problems with kidney function.
Actos and ACTOplus met can cause fluid retention (swelling) that may lead to or worsen heart failure. Talk to your doctor immediately if you experience rapid weight gain, fluid retention or shortness of breath while taking either drug.
Your health professional should perform a blood test to check for liver problems before you start Actos or ACTOplus met and periodically thereafter. Do not take Actos or ACTOplus met if you have active liver disease.
You should also talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine or yellowing of the skin.
For more information, log on to www.actos.com.
* * *
Source: Takeda Pharmaceuticals